Bile acid sequestrants: Glucose-lowering mechanisms and efficacy in type 2 diabetes

Current Diabetes Reports

Volumn 14, Issue 5, 2014, Pages

  Hansen, Morten ^a,b   Sonne, David P ^a,b   Knop, Filip K ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Bile acid sequestrants; Glucose lowering mechanisms; Glycemic control; Mechanism of action; Resins; Type 2 diabetes

Indexed keywords

BILE ACID; BILE ACID SEQUESTRANT; CHOLECYSTOKININ; COLESEVELAM; FARNESOID X RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INCRETIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRANSMEMBRANE G PROTEIN COUPLED RECEPTOR TGR5; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; COLESTILAN; EPICHLOROHYDRIN; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; RESIN;

ANTIDIABETIC ACTIVITY; BILE ACID BLOOD LEVEL; BILE ACID SYNTHESIS; BILE COMPOSITION; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENERGY EXPENDITURE; ENTEROHEPATIC CIRCULATION; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; GLYCOGENOLYSIS; HORMONE RELEASE; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; REVIEW; STOMACH EMPTYING; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; MALE; METABOLISM; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

BILE ACIDS AND SALTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; EPICHLOROHYDRIN; FEMALE; GASTRIC EMPTYING; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIC AGENTS; IMIDAZOLES; INCRETINS; LIPID METABOLISM; MALE; RESINS, SYNTHETIC; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84895775124     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-014-0482-4     Document Type: Review

References (72)

1. Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89:147-91. doi:10.1152/physrev.00010.2008.
2. Kawamata Y, Fujii R, Hosoya M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem. 2003;278:9435-40. doi:10.1074/jbc. M209706200. (Pubitemid 36800434)
3. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun. 2005;329:386-90. doi:10.1016/j.bbrc.2005.01.139. (Pubitemid 40255465)
4. Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009;10:167-77. doi:10.1016/j.cmet. 2009.08.001.
5. Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006;439:484-9. doi:10.1038/nature04330. (Pubitemid 43152840)
6. Out C, Groen AK, Brufau G. Bile acid sequestrants: more than simple resins. Curr Opin Lipidol. 2012;23:43-55. doi:10.1097/MOL.0b013e32834f0ef3.
7. Porez G, Prawitt J, Gross B, Staels B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res. 2012;53:1723-37. doi:10.1194/jlr.R024794.
8. Rosenbaum DP, Petersen JS, Ducharme S, et al. Absorption, distribution and excretion of GT31-104, a novel bile acid sequestrant, in rats and dogs after acute and subchronic administration. J Pharm Sci. 1997;86:591-5. doi:10.1021/js9603820. (Pubitemid 27203407)
9. Heller DP, Burke SK, Davidson DM, Donovan JM. Absorption of colesevelam hydrochloride in healthy volunteers. Ann Pharmacother. 2002;36:398-403. (Pubitemid 34205309)
10. Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med. 1999;159:1893-900. (Pubitemid 29424709)
11. Lyons D, Webster J, Fowler G, Petrie JC. Colestipol at varying dosage intervals in the treatment of moderate hypercholesterolaemia. Br J Clin Pharmacol. 1994;37:59-62. (Pubitemid 24204582)
12. Zieve FJ, Kalin MF, Schwartz SL, et al. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther. 2007;29:74-83. doi:10.1016/j.clinthera.2007.01.003. (Pubitemid 46414026)
13. The Lipid Research Clinics Coronary Primary Prevention Trial results. II The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-74.
14. Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in noninsulin-dependent diabetes mellitus. A short-term, doubleblind, crossover trial. Ann Intern Med. 1994;121:416-22.
15. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med. 2008;168:1975-83. doi:10.1001/archinte.168.18.1975.
16. Fonseca VA, Rosenstock J, Wang AC, et al. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care. 2008;31:1479-84. doi:10.2337/dc08-0283.
17. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med. 2008;168:1531-40. doi:10.1001/archinte.168.14.1531.
18. Neda T, Inukai K, Kurihara S, et al. Hypoglycemic effects of colestimide on type 2 diabetic patients with obesity. Endocr J. 2012;59:239-46.
19. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19:327-36.
20. Braunlin W, Zhorov E, Smisek D, et al. In vitro comparison of bile acid binding to colesevelam HCl and other bile acid sequestrants. Polym Prepr. 2000;41:708-9.
21. Steinmetz KL. Colesevelam hydrochloride. Am J Health Syst Pharm. 2002;59:932-9. (Pubitemid 34522595)
22. Di Angelantonio E, Sarwar N, et al. Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993-2000. doi:10.1001/jama.2009.1619.
23. Donovan JM, Stypinski D, Stiles MR, et al. Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc Drugs Ther. 2000;14:681-90. (Pubitemid 32217192)
24. Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science. 1999;284:1362-5. (Pubitemid 29289663)
25. Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science. 1999;284:1365-8. (Pubitemid 29289664)
26. Wang H, Chen J, Hollister K, et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell. 1999;3:543-53. (Pubitemid 29268438)
27. Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev. 2003;83:633-71. doi:10.1152/physrev. 00027.2002. (Pubitemid 36378680)
28. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005;2:217-25. doi:10.1016/j.cmet.2005.09.001.
29. Goodwin B, Jones SA, Price RR, et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell. 2000;6:517-26.
30. Keitel V, Ullmer C, Häussinger D. The membrane-bound bile acid receptor TGR5 (Gpbar-1) is localized in the primary cilium of cholangiocytes. Biol Chem. 2010;391:785-9. doi:10.1515/BC.2010.077.
31. Keitel V, Donner M, Winandy S, et al. Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun. 2008;372:78-84. doi:10.1016/j.bbrc.2008.04.171. (Pubitemid 351778164)
32. Keitel V, Reinehr R, Gatsios P, et al. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology. 2007;45:695 - 704. doi:10.1002/hep.21458.
33. • Potthoff MJ, Potts A, He T, et al. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. Am J Physiol Gastrointest Liver Physiol. 2013;304: G371- 80. doi:10.1152/ajpgi.00400. 2012. This study establishes the concept that bile acids bound to a BAS can activate TGR5.
34. Maruyama T, Miyamoto Y, Nakamura T, et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun. 2002;298:714-9. (Pubitemid 35356798)
35. Poole DP, Godfrey C, Cattaruzza F, et al. Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system. Neurogastroenterol Motil. 2010;22(814-25): e227-8. doi:10.1111/j.1365-2982.2010. 01487.x.
36. Alemi F, Poole DP, Chiu J, et al. The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice. Gastroenterology. 2013;144:145-54. doi:10.1053/j.gastro. 2012.09.055.
37. Kumar DP, Rajagopal S, Mahavadi S, et al. Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic β cells. Biochem Biophys Res Commun. 2012;427:600-5. doi:10.1016/j.bbrc.2012.09.104.
38. Garbutt JT, Kenney TJ. Effect of cholestyramine on bile acid metabolism in normal man. J Clin Invest. 1972;51:2781-9. doi:10.1172/JCI107100.
39. Angelin B, Björkhem I, Einarsson K, Ewerth S. Hepatic uptake of bile acids in man. Fasting and postprandial concentrations of individual bile acids in portal venous and systemic blood serum. J Clin Invest. 1982;70:724-31. (Pubitemid 12038088)
40. Brufau G, Stellaard F, Prado K, et al. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology. 2010;52:1455-64. doi:10.1002/hep.23831.
41. Brufau G, Bahr MJ, Staels B, et al. Plasma bile acids are not associated with energy metabolism in humans. Nutr Metab. 2010;7:73. doi:10.1186/1743-7075- 7-73.
42. Meissner M, Herrema H, van Dijk TH, et al. Bile acid sequestration reduces plasma glucose levels in db/db mice by increasing its metabolic clearance rate. PLoS ONE. 2011;6:e24564. doi:10.1371/journal.pone.0024564.
43. Sugimoto-Kawabata K, Shimada H, Sakai K, et al. Colestilan decreases weight gain by enhanced NEFA incorporation in biliary lipids and fecal lipid excretion. J Lipid Res. 2013;54:1255-64. doi:10.1194/jlr.M032839.
44. Henry RR, Aroda VR, Mudaliar S, et al. Effects of colesevelam on glucose absorption and hepatic/peripheral insulin sensitivity in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14:40-6. doi:10.1111/j.1463-1326. 2011.01486.x.
45. Schwartz SL, Lai Y-L, Xu J, et al. The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study. Metab Syndr Relat Disord. 2010;8:179-88. doi:10.1089/met.2009.0049.
46. • Smushkin G, Sathananthan M, Piccinini F, et al. The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes. Diabetes. 2013;62:1094-101. doi:10.2337/db12-0923. This study suggests that BASs may decrease meal appearance rate.
47. Beysen C, Murphy EJ, Deines K, et al. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomized controlled study. Diabetologia. 2012;55:432-42. doi:10.1007/s00125-011-2382-3.
48. Adrian TE, Gariballa S, Parekh KA, et al. Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers. Diabetologia. 2012;55:2343-7. doi:10.1007/s00125-012-2593-2.
49. Shang Q, Saumoy M, Holst JJ, et al. Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. Am J Physiol Gastrointest Liver Physiol. 2010;298:G419-24. doi:10.1152/ajpgi.00362.2009.
50. Shang Q, Liu MK, Saumoy M, et al. The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model. Am J Physiol Gastrointest Liver Physiol. 2012;302:G815-23. doi:10.1152/ajpgi.00295.2011.
51. Chen L, McNulty J, Anderson D, et al. Cholestyramine reverses hyperglycemia and enhances glucose-stimulated glucagon-like peptide 1 release in Zucker diabetic fatty rats. J Pharmacol Exp Ther. 2010;334:164-70. doi:10.1124/jpet.110.166892.
52. • Harach T, Pols TWH, Nomura M, et al. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci Rep. 2012;2: 430. doi:10.1038/srep00430. This study show that BASs promote GLP-1 secretion in a TGR5-dependent manner, and that the colon is the major source of the enhanced GLP-1 secretion.
53. Suzuki T, Oba K, Igari Y, et al. Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. J Nihon Med Sch. 2007;74:338-43. (Pubitemid 47523077)
54. Garg SK, Ritchie PJ, Moser EG, et al. Effects of colesevelam on LDL-C, A1c and GLP-1 levels in patients with type 1 diabetes: a pilot randomized double-blind trial.Diabetes ObesMetab. 2011;13:137-43. doi:10.1111/j.1463-1326. 2010.01320.x.
55. • Marina AL, Utzschneider KM, Wright LA, et al. Colesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and β-cell function. Diabetes Care. 2012;35:1119-25. doi:10.2337/dc11-2050. This study show that colesevelam improves oral but not IV glucose tolerance.
56. Watanabe M, Morimoto K, Houten SM, et al. Bile acid binding resin improves metabolic control through the induction of energy expenditure. PLoS ONE. 2012;7:e38286. doi:10.1371/journal.pone.0038286.
57. Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-(7-36) amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology. 1999;140:5356-63.
58. Thomson AB, Keelan M. Feeding rats diets containing cheno- or ursodeoxycholic acid or cholestyramine modifies intestinal uptake of glucose and lipids. Digestion. 1987;38:160-70. (Pubitemid 18054707)
59. Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol. 2010;8:159-65. doi:10.1016/j.cgh.2009.10.020.
60. Psichas A, Little T, Lal S, McLaughlin J. Cholestyramine slows gastric emptying of liquids and reduces appetite in healthy subjects. Neurogastroenterol Motil. 2012;24:1095-101. doi:10.1111/j.1365-2982.2012.01988.x.
61. Maruyama T, Tanaka K, Suzuki J, et al. Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice. J Endocrinol. 2006;191:197-205. doi:10.1677/joe.1.06546. (Pubitemid 44756522)
62. Vassileva G, Hu W, Hoos L, et al. Gender-dependent effect of Gpbar1 genetic deletion on the metabolic profiles of diet-induced obese mice. J Endocrinol. 2010;205:225-32. doi:10.1677/JOE-10-0009.
63. Koop I, Fellgiebel A, Koop H, et al. Effect of cholestyramine on plasma cholecystokinin and pancreatic polypeptide levels, and exocrine pancreatic secretion. Eur J Clin Invest. 1988;18:517-23.
64. Koop I, Dorn S, Koop H, et al. Dissociation of cholecystokinin and pancreaticobiliary response to intraduodenal bile acids and cholestyramine in humans. Dig Dis Sci. 1991;36:1625-32.
65. Kogire M, Gomez G, Uchida T, et al. Chronic effect of oral cholestyramine, a bile salt sequestrant, and exogenous cholecystokinin on insulin release in rats. Pancreas. 1992;7:15-20.
66. Edfalk S, Steneberg P, Edlund H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes. 2008;57:2280-7. doi:10.2337/db08-0307.
67. Hofmann AF. Bile acid sequestrants improve glycemic control in type 2 diabetes: a proposed mechanism implicating glucagon-like peptide 1 release. Hepatology. 2011;53:1784. doi:10.1002/hep.24100.
68. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-93. doi:10.1056/NEJMoa021778. (Pubitemid 36159355)
69. Gall MA, Borch-Johnsen K, Hougaard P, et al. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes. 1995;44:1303-9.
70. Agewall S, Wikstrand J, Ljungman S, Fagerberg B. Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Risk Factor Intervention Study Group. Am J Cardiol. 1997;80:164-9. (Pubitemid 27329215)
71. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-12. (Pubitemid 30609442)
72. Ray KK, Seshasai SRK, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomized controlled trials. Lancet. 2009;373:1765-72. doi:10.1016/S0140-6736(09)60697-8.